logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Portola Pharmaceuticals, Inc.

USPTO Granted Patents = 71

% Expired Patents = 18.3



Trademarks = 4

Forward Citations = 470

Loading Chart...
Loading Chart...

64 inventors (with patents filed for the assignee):

goldMedal Anjali Pandey (35 out of 83 patents)

silverMedal Yonghong Song (26 out of 61 patents)

bronzeMedal Shawn M Bauer (24 out of 30 patents)

4.  Qing Xu (22 out of 54 patents)

5.  Wolin Huang (22 out of 26 patents)

6.  Zhaozhong Jon Jia (18 out of 41 patents)

7.  Robert M Scarborough (16 out of 153 patents)

8.  Mukund Mehrotra (14 out of 20 patents)

9.  Jack W Rose (14 out of 15 patents)

10.  Uma Sinha (14 out of 32 patents)

11.  Genmin Lu (14 out of 20 patents)

12.  Patrick Andre (11 out of 18 patents)

13.  Brian Kane (11 out of 18 patents)

14.  David R Phillips (10 out of 28 patents)

15.  Charles K Marlowe (9 out of 22 patents)


Core Competencies:
Cerdulatinib
Factor Xa Inhibitors
Syk Modulators
JAK Inhibitors
Protein Kinases
Antidotes
Pharmaceutical Compositions
Purification Methods
Unit Dose Formulations
Combination Therapy
Crystalline Forms
Platelet ADP Receptor Inhibitors

71 patents:

1. 12685763 - METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY (2026-07-21),
2. 10851087 - Synthesis of cerdulatinib (2020-12-01),
3. 10765726 - Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same (2020-09-08),
4. 10736895 - Cerdulatinib for treating hematological cancers (2020-08-11),
5. 10675335 - Antidotes for factor Xa inhibitors and methods of using the same (2020-06-09),
6. 10604748 - Preparation of factor Xa derivatives (2020-03-31),
7. 10533001 - Inhibitors of protein kinases (2020-01-14),
8. 10190111 - Antidotes for factor Xa inhibitors and methods of using the same (2019-01-29),
9. 9902688 - Benzamides and nicotinamides as Syk modulators (2018-02-27),
10. 9868729 - Inhibitors of protein kinases (2018-01-16),
11. 9834548 - Pyridazine compounds as JAK inhibitors (2017-12-05),
12. 9676756 - Substituted pyrimidinyl kinase inhibitors (2017-06-13),
13. 9644195 - Compounds and methods for purification of serine proteases (2017-05-09),
14. 9587233 - Antidotes for factor XA inhibitors and methods of using the same (2017-03-07),
15. 9579320 - Inhibitors of syk and JAK protein kinases (2017-02-28),
Company Overview
Portola Pharmaceuticals, Inc., based in South San Francisco, specializes in the development of innovative therapies focused on protein kinase inhibitors. The company is recognized for its advancements in areas such as cerdulatinib, factor Xa inhibitors, and Syk modulators, contributing to the treatment of various hematologic and oncologic conditions. With a strong emphasis on research and development, Portola aims to address unmet medical needs through its expertise in pharmaceutical compositions and purification methods.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Portola Pharmaceuticals, Inc. USPTO Patent Assignee Logo
71 Patents

#21 in South San Francisco, CA

#1,214 in California

#5,169 in US

#10,513 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Portola Pharmaceuticals, Inc.

Forward Citations = 470

64 inventors:

goldMedal Anjali Pandey (35 out of 83 patents)

silverMedal Yonghong Song (26 out of 61 patents)

bronzeMedal Shawn M Bauer (24 out of 30 patents)

4.  Qing Xu (22 out of 54 patents)

5.  Wolin Huang (22 out of 26 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Portola Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/portola-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…